

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-1268 MIS:ac	SERIAL NO. 10/663,722
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT GEORGE A. CATES et al	
		FILING DATE September 17, 2003	GROUP 1642
U.S. PATENT DOCUMENTS			

*INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE
ZL	5,494,673	Feb. 27/96				
ZL	5,612,037	Mar. 18/97				
ZL	5,911,998	Jun. 15/99				
ZL	6,020,182	Feb. 1/00				

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL.	TRANSLATION YES NO
ZL	WO 95/02628	Jan. 26/95				
ZL	WO 96/33738	Oct. 31/96				
ZL	WO 95/34308	Dec. 21/95				
ZL	WO 95/34323	Dec. 21/95				
ZL	WO 98/02457	Jan. 22/98				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ZL	1. Glezen, W.P., et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level (1981). Vol. 98, pp. 708-715.
ZL	
ZL	2. Chanock, R.M., Serious respiratory track disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization (1992) Vol. 90, pp.137-142.
ZL	
ZL	3. Martin, A.J. et al. Epidemiology of respiratory viral infection among paediatric inpatients over six-year period in north-east England (1978), pp. 1035-1038.
ZL	
ZL	4. Robbins, A., and Freeman, P. Obstacles to developing vaccines for the third world. (1988) 259, 126-133.
ZL	
ZL	5. Glezen, W.P., et al. Risk of primary infection and reinfection with respiratory syncytial virus. (1986) 140, pp. 543-546.
ZL	
ZL	6. Katz, S.L. Prospects for immunizing against respiratory syncytial virus. Vol. 1. Washington: National Academic Press. (1985) pp. 397-409.
ZL	
ZL	7. Wertz, G.W., Sullender, W.M. Approaches to immunization against respiratory syncytial virus (1992) Vol. 20, pp.151-176.
ZL	
ZL	8. McIntosh, K. and Chanock, R.M. Respiratory syncytial virus. (1990) pp. 1045-1075.
ZL	
ZL	9. Murry AR, Dowell SF, 1997. Respiratory syncytial virus: not just for kids. Hosp. Pract. (Off Ed) 1997 Jul. 15; 32(7): 87-8, 91-4.

EXAMINER: /Zachariah Lucas/	DATE CONSIDERED: 06/05/2006
-----------------------------	-----------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-1268 MIS:ac	SERIAL NO. 10/663,772
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT GEORGE A. CATES et al	
		FILING DATE September 17, 2003	GROUP 1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
ZL	10. Mlinaric-Galinovic G, Falsey AR, Walsh EE, 1996. Respiratory syncytial virus infection in the elderly. 1996. 15, pp. 777-781	
ZL	11. Collins, P., et al. Respiratory syncytial Virus. (1996) pp.1313-1351.	
ZL	12. Walsh, E.E., Hall, Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. (1987) Vol. 155, pp.1198-1204.	
ZL	13. Walsh, E.E., Hruska, J. Monoclonal antibodies to respiratory syncytial virus proteins: Identification of the fusion protein. (1983) Vol. 47, pp. 171-177.	
ZL	14. Levine, S., et al. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus (1987) Vol. 69, pp. 2521-2524.	
ZL	15. Anderson, L.J., et al. Antigenic Characterization of respiratory syncytial virus strains with monoclonal antibodies (1985), Vol. 151, pp.626-633.	
ZL	16. Johnson, P.R., et al. Antigenic Relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B.... (1987) Vol. 61 (10), pp.3163-3166.	
ZL	17. Cherrie, A.H., et al. Human cytotoxic T cell stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. (1992) J. Virology 66, 2102-2110.	
ZL	18. Kim, H.W., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine (1969) Vol 89, 422-434.	
ZL	19. Friedewald, W.T., et al. Low-temperature-grown RS virus in adult volunteers. (1968) Vol. 204, pp. 142-146.	
ZL	20. Walsh, E.E., et al. Purification and characterization of the respiratory syncytial virus fusion protein. (1985) Vol. 66, pp. 409-415.	
ZL	21. Walsh, E.E., et al. Purification and characterization of GP90, One of the envelope glycoproteins of respiratory syncytial virus. (1984) Vol. 65, 761-766.	
ZL	22. Routledge, E.G., The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice. (1988) Vol. 69, 293-303.	
ZL	23. Fulginiti, V.A., et al. Respiratory Virus Immunization. (1969) Vol. 89 (4), pp. 435-448.	
ZL	24. Chin, J., et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population (1969) Vol. 89 (4), pp. 449-463.	
ZL	25. Kapikian, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) (1969) Vol. 89 (4), pp. 405-421.	
ZL	26. Kim, H.W., et al. Clinical and Immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus. (1971), Vol 48, pp. 745-755.	
ZL	27. Wright, P.F., et al. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children (1982) Vol. 37 (1), pp. 397-400.	
ZL	28. Wright, P.F., et al. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. (1976) Vol. 88, pp.931-936.	
EXAMINER: /Zachariah Lucas/		DATE CONSIDERED: 06/05/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-1268 MIS:ac	SERIAL NO. 10-663,722
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT GEORGE A. CATES et al	
		FILING DATE September 17, 2003	GROUP 1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
ZL	29. Belshe, R.B., Parenteral administration of live respiratory syncytial virus vaccine; results of a field trial. (1982) Vol. 145, pp 311-319.	
ZL	30. Murphy, B.R., et al. Dissociation between serum neutralizing and glycoprotein antibody response of infants and children who received inactivated respiratory syncytial virus vaccine(1986), 24(2), 197-202.	
ZL	31. Connors, M., et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia -RSV recombinants or RSV. (1992) Vol. 10, pp. 475-484.	
ZL	32. Prince, G.A., et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. (1986) Vol. 57 (3), pp. 721-728.	
ZL	33. Piedra, P.A., et al. Immune response to experimentally induced infection with respiratory syncytial virus: Possible role in the development of pulmonary disease. (1989) Vol. 70, pp. 325-333.	
ZL	34. Payne G.L., et al. Vaccine Vol. 16. pp. 92-98 1998.	
ZL	35. Fattom Ali et al. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. (1999) Vol. 17 pp. 126-133	
ZL	36. Ambrosch F. et al. Combined vaccination against yellow fever a comparative trial. 1994 Vol. 12 pp. 625-628.	
ZL	37. Frey Sharon et al. Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/Hepatitis B Vaccine 1999; 180 pp. 2018-2022.	
ZL	38. Insel, A. Richard., Potential alterations in Immnogenicity by Combining or Simultaneously Administering Vaccine Components. pp. 35-47. 1995	
ZL	39. Plotkin A.S. et al. Vaccines. Third Edition pp. 508-530. 1998	
EXAMINER: /Zachariah Lucas/		DATE CONSIDERED: 06/05/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.